DTC TV and radio prescription drug ads must present the major risk statement in consumer-friendly language, at comparable audio quality, with concurrent on-screen text on TV and without distracting elements.
21 CFR 202.1(e)(1)(i)-(ii)
Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.
21 CFR 202.1(e)(1), (e)(2)(i), (e)(5)(ii), (e)(7)(viii); 21 CFR 201.57(c)(1); 21 U.S.C. 352(n)
Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6), (e)(7)
Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.
21 CFR 202.1; 21 U.S.C. 352(n); FDA Draft Guidance, Help-Seeking and Other Disease Awareness Communications (Jan. 2004) secs. III.A, IV
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(4)(i)(a), (e)(5)(ii), (e)(6)
Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)(ii), (e)(6)(i), (e)(6)(xix), (e)(7)(x); 21 CFR 201.57(c)(9)(iv)-(v)
Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.
21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6)(i), (e)(6)(iv); 21 U.S.C. 352(a), (n)